We are honored and excited to participate and contribute to the new KG Jebsen Center for Myeloid Blood Cancer.
The main goal is to develop diagnostics at the single-cell level that reveal response to treatment after hours and days, and use this information to optimize or replace the planned treatment. The Center is supported by generous funds from the Stiftelsen Kristian Gerhard Jebsen, the University of Bergen, Helse Bergen, the Blood Cancer Society and the Norwegian Cancer Society.
Venue for the opening symposium is Grand Bergen, Nedre Ole Bulls plass 1, 5012 Bergen
Wednesday 11. September, Grand Bergen
10:30 Registration, Coffee
11:00-12:00 Opening
11:00-11:10 Bjørn Tore Gjertsen, C-MYC Centre Director
11:15-11:20 Anne Marie Haga, KG Jebsen Foundation
11:25-11:35 Olav Ljøsne, Chair, Blodkreftforeningen
11:35-11:40 Per Bakke, Dean, Medical Faculty, University of Bergen
11:45-11:50 Clara Gjesdal, vice CEO, Haukeland University Hospital
11:55-12:00 Silke Appel, Chair, Department of Clinical Sciences, University of Bergen
12:00-12:05 Kahtan Al-Azawy, Director, Department of Medicine, Haukeland University Hospital
12:05-13:20 Lunch
Scientific Program
13:20-14:00 Targeting Epigenetics: A new strategy in myeloid cancer prevention? Kirsten Grönbæk
14:00-14:40 Molecular Measureable Residual Disease Monitoring in Acute Myeloid Leukemia (AML), Konstanze Döhner
14:40-15:20 What is meant by “responsible” cancer research? Roger Strand, CCBIO, Centre for the Study of the Sciences and the Humanities
15:20-15:30 Concluding remarks and introduction of Symposium Day 2, Bjørn Tore Gjertsen
Thursday 12. September, Grand Bergen
08:30 Registration, Coffee
Chair: BT Gjertsen
09:00-09:20 Demultiplexing cell identity, Simona Chera, KGJ C-MYC
09:20-09:40 Towards single-cell profiling of translation and isoforms, Eivind Valen, KGJ C-MYC
09:40-10:00 Minimal Residual disease in myelodysplastic syndrome, Astrid Olsnes
10:00-10:20 Allogeneic hematopoietic stem cell transplantation for myeloid malignancies – from patient’s bed to multiomics? Håkon Reikvam
10:20-10:30 Pause
Chair: S Chera
10:30-10:50 Novel approaches to the prevention of acute graft versus host disease, Yngvar Fløisand
10:50-11:10 AML modelling: Past, present and future directions, Emmet Mc Cormack
11:10-11:30 How can we make use of the p53 code in the clinic? JC Bourdon
11:30-12:00 Functional precision medicine for overcoming drug resistance in elderly/unfit AML patients, Krister Wennerberg
12:00-12:50 Lunch
Chair: E Valen
12:50-13:10 Generating evidence from Real World Data in hematology, Kimmo Porkka
13:10-13:30 Evolutionary landscape of clonal hematopoiesis, Gerwin Huls
13:30-14:10 Novel candidate targets for future AML therapies: Glycosaminoglycans and DNA-PK, Kim Theilgaard-Mönch
14:10-14:30 Targeting NAMPT in -7/-7q Myeloid Blood Cancers, Caroline Heckman
14:30-14:40 Pause
Chair: H Reikvam
14:40-15:00 Clinical forecasting of Acute Myeloid Leukemia by ex vivo drug sensitivity screening, Jorrit Enserink
15:00-15:20 Ex Vivo Venetoclax Sensitivity Testing Predicts Treatment Response in AML, Mika Kontro
15:20-15:40 A phase 1 study to study 5-FU-mir-15a (CR-001) in AML, Andrea Lenartova
15:40-16:00 Quality of life studies in AML in Sweden, Vladimir Lazarevic
16:00-16:20 Metabolic rewiring as targetable entity in AML, JJ Schuringa
16:20-16:40 Closing remarks, Simona Chera (Co-Director, C-MYC)